Nventa strengthens patent portfolio with two new European Patents for HPV-related diseases

22-Jun-2006

Nventa Biopharmaceuticals Corporation announced that the European Patent Office has granted two patents to Nventa related to HspE7, its investigational therapeutic vaccine for the treatment of human papillomavirus (HPV)-related diseases. HspE7 consists of a heat shock protein (Hsp) covalently fused to an HPV E7 viral protein to form one CoVal(TM) therapeutic protein.

Patent Number EP 1,296,711 B1, "HPV E7 For Human Papilloma Virus Treatment," covers the use of Nventa's HPV-16 based CoVal(TM) fusion protein HspE7, for the treatment of HPV-related diseases not caused by HPV-16. The patent addresses and provides Nventa protection around observations made from earlier studies that show clinically relevant responses in diseases such as genital warts.

Patent Number EP 1,336,621 B1, "Immune Responses Against HPV Antigens Elicited by Compositions Comprising HPV Antigens and Stress Proteins or an Expression Vector Capable of Expression of These Proteins," provides further coverage for HspE7 with specific claims for the composition of Hsp-HPV E7 fusion proteins and their use for manufacturing drugs that induce an immune response against HPV protein antigens.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances